Bind stock soars on 2015 update; GW Pharma as Sativex misses in PhIII; Kyowa, Syndax ink $100M license deal;

@FierceBiotech: Biogen Idec's remyelination drug raises hopes--and some fears--in Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Anybody who says that statistical significance is not expected in a study is playing defense for a stock. | Follow @JohnCFierce

@DamianFierce: No FDA panel scheduled for Pizer's palbociclib, which $PFE hopes to get approved as Ibrance before April deadline. More | Follow @DamianFierce

> Bind Therapeutics ($BIND) saw its share price soar 80% this morning as the biotech laid out its 2015 strategy and updated investors on a positive mid-stage study of BIND-014 for castration-resistant prostate cancer. Release

> Shares of GW Pharmaceuticals slid this morning after the UK biotech reported that Sativex failed the first of three Phase III pain studies. Story

> Kyowa Hakko Kirin and Syndax Pharmaceuticals inked a $100 million license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Alere snags first FDA CLIA waiver for molecular influenza test. Article | Follow @FierceMedDev

@EmilyWFierce: Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Story | Follow @EmilyWFierce

> 23andMe's $60M deal with Genentech shows an alternative path forward for diagnostics companies. News

> FDA lifts import restriction on Hospira as it aims to reinvigorate its infusion pumps. Article

Pharma News

@FiercePharma: ICYMI yesterday: New study clears Merck's blockbuster Gardasil of MS risk. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Valneva picks up J&J's cholera vaccine--and some forthcoming competition. More | Follow @CarlyHFierce

> Big Pharma threatens to sue U.K. fund as officials nix Novartis, Sanofi and Eisai meds. More

> Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Article

Vaccines News

> Pfizer's growth spurt continues with pickup of Switzerland's Redvax. Report

> Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose. Article

> Valneva picks up J&J's cholera vaccine--and some forthcoming competition. Story

> No link between Merck's Gardasil and MS risk, study shows. Item

> Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late? More

Pharma Manufacturing News

> Impax Labs overcomes manufacturing issues to get Parkinson's drug approved. More

> Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch. Article

> France and Italy ban products from Indian companies. More

> Drugmakers ask Supreme Court to squelch California drug takeback law. Story

> China regulator promises action to fix 'grim' drug safety situation. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.